2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
240
Lymphoma
178
Lymphoma, Large B-Cell, Diffuse
172
Precursor Cell Lymphoblastic Leukemia-Lymphoma
87
Lymphoma, Follicular
79
Lymphoma, Non-Hodgkin
73
Burkitt Lymphoma
66
Multiple Myeloma
64
Leukemia
57
Hodgkin Disease
45
Lymphoma, Mantle-Cell
41
Neoplasms
34
Lymphoma, T-Cell, Peripheral
31
Lymphoma, B-Cell
30
Lymphoma, B-Cell, Marginal Zone
28
Lymphoma, Large-Cell, Anaplastic
26
Neoplasm Metastasis
25
Lymphoma, Large-Cell, Immunoblastic
24
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
22
Leukemia, Lymphocytic, Chronic, B-Cell
22
Neoplasms, Plasma Cell
21
Recurrence
20
Immunoblastic Lymphadenopathy
15
Dendritic Cell Sarcoma, Interdigitating
15
Lymphoma, T-Cell
14
Leukemia, Biphenotypic, Acute
10
Waldenstrom Macroglobulinemia
9
Blast Crisis
9
Primary Myelofibrosis
8
Myelodysplastic Syndromes
8
Interventions
enzalutamide
5
abiraterone
2
Radiotherapy
2
Metastasectomy
2
Abiraterone Acetate
2
testosterone enanthate
1
radium Ra 223 dichloride
1
pembrolizumab
1
disitamab vedotin
1
dactolisib
1
VT-464
1
Radium-223
1
Radiosurgery
1
Prednisone
1
NVP-BKM120
1
Ketoconazole
1
Injections
1
Hydrocortisone
1
Flutamide
1
Cyclophosphamide
1
Crizotinib
1
Control Groups
1
Carboplatin
1
Calcitriol
1
Blood Specimen Collection
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Castration-resistant Prostate Cancer
×
Prednisone
×
Clear all
NCT02429193
2020-01-13
BARRIER-P
University Health Network, Toronto
Phase 2
Completed
16 enrolled